Navigation Links
Medical Marijuana Inc. and Canipa Holdings Drive Dixie X and CanChew Gum Toward EU Marketing Approval And Clinical Development
Date:8/1/2012

SAN DIEGO, Aug. 1, 2012 /PRNewswire/ -- Medical Marijuana Inc. (OTC: MJNA), a leading hemp industry innovator, is pleased to provide an update on the efforts of Canipa Holdings in regards to European Union marketing approvals for MJNA Portfolio Products including the Dixie X Brand and CanChew gum

Approval Process

Canipa Holdings is currently working with European Health Authorities and their Governmental counterparts to obtain marketing approvals for the Dixie X and CanChew gum hemp-based, CBD-infused products. We expect preliminary approval in 60 days and final approval 30 days after. Once approved, these products will be sold "over-the-counter" throughout Romania and the remaining 26 European Union Member Countries.

Pending Clinical Studies

Simultaneous to the marketing approvals, MJNA and Canipa Holdings are working with authorities to provide European FDA-level clinical studies. While there have been numerous, positive studies on the effects of Cannabinoids (CBD's), the Company's specific CBD-infused products will be studied by selected EU medical universities. Initially it is anticipated that the studies will prove the safety and efficacy of these products in the treatment of chronic pain.

Further clinical trials will be commissioned to study the effect of the CBD-infused products on muscle spasticity and nausea. Muscle spasticity, which affects many spinal cord injury and neuro-degenerative patients (such as Multiple Sclerosis) can create pain through nerve
'/>"/>

SOURCE Medical Marijuana Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Center for Medicare & Medicaid Innovation Awards $19 Million Grant to Develop Oncology Medical Home Model
2. Infuse Medical unveils EtherDCP for Mobile Application Management (MAM)
3. Leading Medical Technology Company Selects inContact to Transform Service Experience
4. The Outlook for Medical Devices in Latin America
5. The Outlook for Medical Devices in Western Europe
6. The Outlook for Medical Devices in Central Asia
7. The Outlook for Medical Devices in South East Asia
8. Medical Sales College Boasts An 81.99% Placement Rate For 2011 Graduates
9. Medical Affairs Plays Important Role in the Success of New Product Planning Programs
10. Disability Advocates Tell Medicare: Use a Clinical Template to Accurately Document Medical Need for Wheelchairs
11. Novogen Announces Merger Agreement With Kai Medical And Distribution Of Mei Pharma Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 1, 2014   Intarcia Therapeutics, Inc. today ... phase 3 clinical trials for ITCA 650 (exenatide, delivered ... osmotic mini-pump). The first trial, FREEDOM-1, was a placebo-controlled, ... and safety of ITCA 650 in patients with type ... to be significantly superior to placebo for both 40 ...
(Date:10/1/2014)... 1, 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technology used to develop and produce enzymes ... biopharmaceuticals, and industrial enzymes industries, today announced the ... Bioenergy for commercial scale production of Abengoa,s proprietary ... developed under Abengoa,s license agreement with Dyadic. ...
(Date:10/1/2014)... NeuroCall, Inc., ("NeuroCall") announced today that it ... Teleneurology services. Dr. Ricardo Garcia-Rivera , Founder and ... proud that our quality of service has been recognized ... lifesaving support and continuity of care to patients of ... the United States ." NeuroCall ...
Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3NeuroCall Awarded Joint Commission Accreditation 2
... Ltd. (NYSE Amex: CPD ) announced that ... (Sun) have been extended until January 28, 2012 but ... which was originally set to expire in January 2010, ... and is being extended for an additional 1 year ...
... Pharmaceutical Company (NYSE: KVa/KVb) today announced the filing of its ... with the Securities and Exchange Commission.  As a result, the ... 2010 Form 10-K to enable its securities to continue trading ... is currently working on preparing and filing its quarterly reports ...
Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma 2Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma 3K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 2K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 3K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 4K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 5K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 6K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 7K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 8
(Date:10/2/2014)... Dennis Thompson HealthDay ... -- Hospitals that pull out all the stops to ... saving lives, but the cost of such heroism is ... are about 5 percent better at saving elderly patients ... that operate with less intensity, said senior author Dr. ...
(Date:10/2/2014)... by scientists at The University of Nottingham could lead ... painkiller. , A drug resulting from the research, published ... offer new hope to sufferers of chronic pain conditions ... painkillers are currently available. , The work, led by ... Sciences, in collaboration with David Bates, Professor of Oncology ...
(Date:10/1/2014)... The peptide a small protein beta-amyloid is strongly associated ... unequivocal proof that this peptide is the causal agent ... main obstacle impeding such confirmation is that beta-amyloid is ... it aggregates, that is when it self-assembles to form ... with a single target, beta-amyloid alone, but with multiple ...
(Date:10/1/2014)... in the Journal of the American Medical Association ... with moderate or severe chronic knee pain, acupuncture did ... of Melbourne randomly assigned 282 patients (50 years or ... sham or pretend laser treatment. , Treatments were ... to laser and sham (inactive) laser acupuncture. , Researcher ...
(Date:10/1/2014)... and Physical Sciences Research Council (EPSRC) will focus ... control systems which run, for example, manufacturing plants, ... network. , The research will help understand ... the systems behind our critical national infrastructure. ... Systems (RITICS), based at Imperial College London, is ...
Breaking Medicine News(10 mins):Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Medical discovery first step on path to new painkillers 2Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2
... By studying the addition of sugars to proteins ... nervous system of insects, Karen Palter, researcher of ... to better understand neurodegenerative diseases in humans. Currently, ... projects exploring the glycosylation process that could eventually ...
... has increased in recent years, the Washington Post reports. ... and the American Society of Aesthetic Plastic Surgery, while ... medicine procedures, the number of blacks, Hispanics and Asians ... five years. In 2002, minorities accounted for 16% of ...
... Evidence is accumulating that depression is a risk factor ... Women's Health Watch. A recent study found that ... called selective serotonin reuptake inhibitors (SSRIs) had double the ... Other research points to depression itself as a source ...
... development and spread of drug-resistant tuberculosis (TB), the Stop TB ... Global Drug Facility, has provided anti-TB drug treatments for 10 ... ,"This is an important milestone, because getting anti-TB ... complete their treatment is the only way to break the ...
... the myriad strains of the human immunodeficiency virus (HIV) ... conducted at the Uniformed Services University of the Health ... variable, its prevention requires a vaccine effective enough to ... neutralise multiple viral strains. ,The latest ...
... Girls actress Lindsay Lohans father, Michael, believes now that his ... change her life completely. ,Lohan is currently ... in Malibu. ,Michael believes that Lohan can ... negative influence. ,"I'm glad she's there and ...
Cached Medicine News:Health News:Nervous Systems of Insects may Offer Clues on Neurodegenerative Diseases 2Health News:Nervous Systems of Insects may Offer Clues on Neurodegenerative Diseases 3Health News:Stop TB Partnership Has Provided Treatments for Ten Million People in Six Years 2
Small pupil irrigating nucleus chopper, wedge-shaped inferior edge with, blunt tip and front notch, for engaging the iris, 0.6 mm dual sideports, 20 gauge....
Irrigating nucleus chopper, 0.6 mm dual sideports, 20 gauge. For the right handed surgeon....
Karate phaco chopper, semi-sharp, wedge shaped inferior edge with a pointed tip...
Phaco chopper, short (0.75 mm) pointed "quick chop" tip....
Medicine Products: